A New HS Injection Could Mean Dosing Just Once a Month
My AccountFIND A DOCTORNewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSmileSun CareTreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin ConditionsSkin Lifting and TighteningBodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessFitnessGLP-1sHealthMenopauseNewBeauty RXBEAUTYPASSNewsView All NewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceView All FaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSmileSun CareTreatmentsView All TreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin ConditionsSkin Lifting and TighteningBodyView All BodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairView All HairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsView All AwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingView All ShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessView All WellnessFitnessGLP-1sHealthMenopauseNewBeauty RXLoading…FIND A DOCTORBEAUTYPASS Advertisement Home›Skin Care›Chronic Skin Conditions A New HS Injection Could Mean Dosing Just Once a Month The phase 2 results cleared a high bar for improvement. Current biologics for moderate to severe hidradenitis suppurativa (HS) target TNF or IL-17, two drivers of inflammation. A new injectable headed toward larger trials takes a different approach, and its early results are turning heads. As reported by Dermatology Times, Avalo Therapeutics announced positive results from a phase 2 trial of abdakibart, an injectable treatment for adults with moderate to severe HS.